Author

Connor G Burke

Van Andel Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Alexander C. MonovichiD· 1 shared Colton Dysart· 1 shared Dahlya Kamarudin· 1 shared Darrell P. ChandleriD· 1 shared Eve Deering-GardneriD· 1 shared Joanna S. YiiD· 1 shared Monika W. PereziD· 1 shared Nathaniel J. ButeyniD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander C. MonovichORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

EZH2-driven immune evasion at disease presentation defines atargetable high-risk subset of acute leukemia exemplified byt(16;21) FUS::ERG AML

Nathaniel J. Buteyn, Samantha J LaMantia, Connor G Burke, Vincent J Sartori, Yizhou Peter Huang, Colton Dysart, Eve Deering-Gardner, Zachary J. DeBruine, Dahlya Kamarudin, Darrell P. Chandler, Alexander C. Monovich, Monika W. Perez, Joanna S. Yi, Rhonda E. Ries, Todd A. Alonzo, , Timothy Junius Triche

This paper identifies an EZH2-driven immune evasion phenotype in FUS::ERG AML that is reversible with tazemetostat, offering a potential targeted therapy for high-risk acute leukemia.

Blood Neoplasia · Sep 1, 2026Peer-reviewedCancer Biology